In three types of human cancer samples (23 MM, 1 ovarian cancer and 1 sarcoma sample), researchers have recently proposed that application of the combination assays of total intracellular CD137 expression, tumor reactive cytokines (IFN-γ and TNF-α) and scRNA analysis data could obtain the rapid and accurate in vitro identification of a larger proportion of TSTs, such a cell population not only had the specificity to recognize tumor neoantigens but also had immediate tumor responsiveness. The gene discussed is TNFRSF9; the disease is ovarian carcinoma.